An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 928, Issue , 2013, Pages 93-37

  Zheng, Yi ^a   Thomas Schoemann, Audrey ^a,b,c   Sakji, Lilia ^d   Boudou Rouquette, Pascaline ^a,b,e   Dupin, Nicolas ^e   Mortier, Laurent ^d   Vidal, Michel ^a,b,c   Goldwasser, Francois ^a,b,e   Blanchet, Benoit ^a,b,c  

^a Unité Fonctionnelle de Pharmacocinétique et Pharmacochimie ^*  (France)

^b Centre d étude et de recours sur les inhibiteurs de l angiogénèse CERIA   (France)

^c CNRS   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cancer patients; Erlotinib; Liquid chromatography; Therapeutic drug monitoring; UV detection; Vemurafenib

Indexed keywords

CANCER PATIENTS; ERLOTINIB; THERAPEUTIC DRUG MONITORING; UV DETECTION; VEMURAFENIB;

AMINO ACIDS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PATIENT MONITORING; PLASMAS;

DISEASES;

ACETONITRILE; ERLOTINIB; GLYCINE; SORAFENIB; VEMURAFENIB;

ACCURACY; ARTICLE; CALIBRATION; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; PRIORITY JOURNAL; ULTRAVIOLET RADIATION;

CARCINOMA, NON-SMALL-CELL LUNG; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HUMANS; INDOLES; LIQUID-LIQUID EXTRACTION; MELANOMA; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET; SULFONAMIDES;

EID: 84876465084     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2013.03.017     Document Type: Article

References (13)

1. Cantwell-Dorris E.R., O'Leary J.J., Sheils O.M. Mol. Cancer Ther. 2011, 10:385.
2. Keating G.M. BioDrugs 2012, 26:325.
3. Bollag G., Tsai J., Zhang J., Zhang C., Ibrahim P., Nolop K., Hirth P. Nat. Rev. Drug Discov. 2012, 11:873.
4. European Medicine Agency. , p. 35. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002409/WC500124400.pdf.
5. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. N. Engl. J. Med. 2010, 363:809.
6. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Nature 2012, 483:100.
7. Sparidans R.W., Durmus S., Schinkel A.H., Schellens J.H., Beijnen J.H. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci 2012, 889-890:144.
8. FDA, U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), 2001.
9. Faivre L., Gomo C., Mir O., Taieb F., Schoemann-Thomas A., Ropert S., Vidal M., Dusser D., Dauphin A., Goldwasser F., Blanchet B. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2011, 879:2345.
10. Passing H., Bablok J. Clin. Chem. Clin. Biochem. 1983, 21:709.
11. Bland J.M., Altman D.G. Lancet 1986, 1:307.
12. Finn L., Markovic S.N., Joseph R.W. BMC Med. 2012, 10:23.
13. Honeywell R., Yarzadah K., Giovannetti E., Losekoot N., Smit E.F., Walraven M., Lind J.S., Tibaldi C., Verheul H.M., Peters G.J. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2010, 878:1059.